Shanghai Healthcare M&A Fund Strategically Acquires Chengdu Kanghua Biological, Establishing a Fully Integrated Ecosystem
HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - Chengdu Kanghua Biological Products Co., Ltd. (Stock Code: 300841.SZ) announced that Shanghai Healthcare M&A Fund ("the M&A Fund") intends to acquire the Company through a strategic agreement. Leveraging its substantial resource and financial strength, the M&A Fund plans to support Kanghua Biological's established product portfolio, accelerate sales of its mature products, and develop industry synergies between Shanghai and Chengdu. The goal is to rapidly expand a diversified vaccine pipeline and build an integrated vaccine ecosystem that combines proven commercialized products with best-in-class R&D capabilities.The vaccine industry is an essential pillar of public health with high entry barriers, stringent oversight, and extended development cycles – all factors contributing to its significant growth potential. As a leading domestic vaccine producer, Kanghua Biological's flagship product - human diploid cell rabies vaccine – stands as China's first domestically developed premium vaccine with over a decade of safe application, established market presence and nationwide distribution. The Company also maintains a robust global innovation pipeline, having successfully licensed its recombinant hexavalent norovirus vaccine overseas. This strategic acquisition, focused on critical segments of the vaccine value chain, will strengthen its strategic positioning. The M&A Fund is committed to supporting Kanghua Biological in leveraging its core product line while harnessing the combined strengthens of Shanghai and Chengdu to accelerate the formation of a next-generation vaccine industry ecosystem.This acquisition marks a significant step to drive Shanghai and Chengdu biopharmaceutical cooperation. Post-transaction, Kanghua Biological will capitalize on Shanghai's advanced R&D resources and access to top-tier scientific talent and global capital to enhances its industrial capabilities, manufacturing capacity, and market penetration. The M&A Fund will consolidate diverse industrial assets to promote Kanghua Biological's integration with Shanghai's R&D and clinical networks, creating an end-to-end collaborative system that spans from "clinical R&D to commercialization" and accelerates the development of a full industrial value chain."This transaction goes beyond a typical corporate acquisition, it represents a transformative catalyst for industrial upgrading,""This exemplifies the complementary strengths created by resource-empowered consolidation. With deep biopharmaceutical, financial, R&D, and global network expertise, Shanghai Healthcare M&A Fund will create significant synergies with Kanghua Biological's technologies, products, manufacturing, and domestic distribution to have an outsized impact on the sector."Hashtag: #SIICCapital #ChengduKanghuaBiological #ShanghaiHealthcareM&AFund
The issuer is solely responsible for the content of this announcement.
About Shanghai Healthcare M&A Fund
A core component of Shanghai's state-owned capital fund network, Shanghai Healthcare M&A Fund is managed by SIIC Capital, a subsidiary of SIIC Group. The M&A Fund targets Shanghai's biopharmaceutical sector, aligning government policy objectives with industrial needs by fostering collaboration with leading industry companies, strengthening sector clusters, and enabling asset restructuring. Through capital infusion, improving governance, optimizing management, and executing M&A, the M&A Fund backs "anchor" companies to build complementary and reinforcing links in the value chain, driving the ongoing transformation of specialized subsectors.
About Chengdu Kanghua Biological Products Co., Ltd.
Chengdu Kanghua Biological Products Co., Ltd. is a biopharmaceutical company engaged in research, manufacture and commercialization of biological products. Established in 2004, the company operates an in-house testing center and GMP-certified bacterial and viral vaccine production facilities. Its marketed portfolio includes the ACYW135 meningococcal polysaccharide vaccine and a freeze-dried human diploid cell rabies vaccine. Kanghua holds GMP certification from China's National Medical Products Administration, has participated in numerous scientific research projects and has been granted patents for over 100 technologies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
6 hours ago
- The Star
US Treasury chief says trade talks with China to continue this week in Sweden
US Treasury Secretary Scott Bessent has said that he would meet his Chinese counterparts in Sweden this week to continue trade talks between the two countries, suggesting the current pause in sky-high tariffs aimed at each other could be extended. Bessent told Fox Business that he would speak with Chinese officials on Monday and Tuesday for a third round of high-level talks in Stockholm – following face-to-face discussions he held with Chinese Vice Premier He Lifeng in Geneva and London – to work out a likely extension of the pause beyond mid-August. Beijing has yet to confirm the Stockholm talks, but Swedish Prime Minister Ulf Kristersson said in a post on X on Tuesday that his country would play host to the US-China negotiations next week. After US President Donald Trump's announcement of 'reciprocal' tariffs on April 2, Washington and Beijing raised punitive levies on each other's exports to triple-digit percentage levels. Since then, trade relations have thawed somewhat as the countries have engaged in talks, marked by a June telephone call between Trump and Chinese President Xi Jinping. On Monday Bessent said that the talks were 'in a good place', a sanguine take on negotiations echoed by Beijing's embassy in Washington, which said 'new progress' had been made in resolving each other's economic and trade concerns. Separately on Tuesday, Trump told reporters that Xi has invited him to visit Beijing and that he would accept. He added that exports of rare earth and magnets to the US may no longer be a thorny issue. 'President Xi has invited me to China, and we'll probably be doing that in the not too distant future, a little bit out, but not too distant. And I've been invited by a lot of people, and we'll make those decisions pretty soon,' he said during a meeting in the Oval Office with Philippine President Ferdinand Marcos Jnr. 'We have a very good relationship. In fact, the magnets, which is a little complex piece of material, but the magnets are coming out very well. They're sending them in record numbers. We're getting along with China very well,' said Trump. In a possible signal of improving ties, China's market administration watchdog said earlier on Tuesday that it had suspended its anti-trust probe into American multinational chemical company DuPont. Beijing launched its investigation into DuPont in early April, after Trump began slapping new levies on Chinese goods. Bessent said on Monday that he hoped to raise in future talks the issue of China's purchases of Russian and Iranian oil. Beijing's embassy in Washington responded to those comments by saying that 'the international community, including China, has conducted normal cooperation with Iran and Russia within the framework of international law. 'This is reasonable and lawful without harm done to any third party, and deserves to be respected and protected,' said the embassy. China observers said that Beijing would oppose Washington's bid to link tariff talks to Chinese relations with US adversaries. 'Beijing sees its ties and transactions with Russia and Iran as just and fair and conforms to international laws and may be unlikely to make compromises for the sake of US lowering tariffs,' said Xin Qiang, an international studies professor at Fudan University in Shanghai. 'Beijing is mindful not to fall into the trap as US uses tariffs to pursue its geopolitical agenda.' During the Fox Business interview Bessent also mentioned his expectations for China's government to rein in manufacturing overcapacity and launch structural adjustments to stimulate domestic consumption to benefit American manufacturing. 'President Trump is remaking the US into a manufacturing economy. If we could do that together – more U.S. manufacturing, more Chinese consumption – that would be a home run for the Chinese Communist Party and the global economy,' he said. - SOUTH CHINA MORNING POST
The Star
7 hours ago
- The Star
China and Russia relaunch maritime research missions, eyeing Arctic ambitions
For the first time in five years, China and Russia have set sail on a joint oceanographic expedition, a research mission to learn more about the evolution of oceans and the forces behind global climate change. A total of 25 members from the two countries are on board the research ship Akademik M.A. Lavrentyev, which left the port of Vladivostok on Tuesday, according to China's First Institute of Oceanography (FIO) under the Ministry of Natural Resources. The ninth such expedition for the two countries – and the first since the pandemic – is focused on the effects of a changing climate on deep-sea environments, according to Chinese authorities. The expedition, jointly launched by FIO and the Pacific Oceanological Institute (POI) at the Far East Branch of the Russian Academy of Sciences, is expected to last 45 days, during which researchers will conduct environmental surveys in the Bering Sea and the northwestern Pacific Ocean. They will explore the response systems and feedback effects in the region over the last 126,000 years, a period known as the Late Quaternary. The FIO said on its website that the scientists would investigate source-to-sink sediment processes, which are the cycles of deposit movement from land into water. 'The resumption of China-Russia joint oceanographic surveys shows [a] shared commitment to addressing global climate change and exploring cutting-edge marine science, and marks a new chapter in bilateral marine research cooperation,' said Wang Jun, acting head of the Chinese consulate general in Vladivostok, according to a report by state news agency Xinhua. Denis Makarov, director of the POI, said the research would help to reconstruct the evolution of oceans and climate to better predict the impact of current and future climate change on regional marine ecosystems, fisheries, transport and other related fields. A total of 110 Chinese scientists have taken part in the joint expeditions since they were first launched in 2010, according to the ministry. The research areas have expanded beyond the Sea of Japan – also known as the East Sea – the Sea of Okhotsk and the Bering Sea and now include several Arctic areas, including the Chukchi, East Siberian, Laptev and Kara seas. Aside from maritime expeditions, the two countries have also collaborated on projects such as the first China-Russia Marine Science Symposium, held in Qingdao, in eastern China's Shandong province in 2009. The event attracted more than 120 scientists from 25 Russian and Chinese research institutions. In 2017, the FIO and POI set up a joint research centre on oceanology and climate, the ministry said. Last year, the two nations agreed to set up a subcommittee to cooperate on the Northern Sea Route – which spans 5,600km (3,500 miles) from the Barents Sea near Scandinavia to the Bering Strait near Alaska – amid growing geopolitical tensions between both countries and the West. The effort is aimed at promoting the role of Arctic passages in international sailing, improving icebreaker capacities, and encouraging Sino-Russian shipping cooperation in the region. The collaboration on the Northern Sea Route is also focused on sailing development, shipping security, and vessel technology and construction for the Arctic. In addition to the Northern Sea Route along Russia's northern coastline, Beijing has been considering the viability of two other Arctic passages: the Northwest Passage running mostly through Canadian waters and a potential transpolar route crossing the North Pole. Beijing put forward its plan for a 'Polar Silk Road' – as a complement to its massive infrastructure scheme, the Belt and Road Initiative – in a 2018 white paper that envisioned greater access to the Arctic's rich natural resources and a bigger role in its governance. Besides scientific research and commercial shipping, maritime defence has also been a priority. In October, the Chinese coastguard joined its Russian counterpart on a patrol for the first time, sailing from the North Pacific to the Arctic Ocean. In March, China held a joint naval exercise with Russia and Iran in the Indian Ocean, which included simulated attacks on maritime targets, joint search and rescue drills, and spot checks and arrests. -- SOUTH CHINA MORNING POST
The Star
8 hours ago
- The Star
Tariff uncertainty to weigh on Bursa Malaysia this week
KUALA LUMPUR (Bernama): The risk of higher United States (US) tariffs on Malaysia as the Aug 1 deadline draws near is likely to weigh on Bursa Malaysia from Monday (July 28), although domestically-oriented counters are expected to remain relatively resilient, supported by firm internal demand and fiscal tailwinds. UOB Kay Hian Wealth Advisors Sdn Bhd head of investment research Mohd Sedek Jantan said volatility is expected to intensify as markets approach a critical inflection point in global trade policy. "Domestically-oriented counters on Bursa Malaysia are likely to remain relatively resilient. However, export-driven sectors may continue to face pressure in the absence of a favourable resolution to the tariff negotiations,' he told Bernama. He noted that no formal announcement has been made on the revised US tariff schedule for Malaysia. "Should Malaysia succeed in securing a rate below the symbolic 20 per cent threshold, we anticipate renewed investor interest, particularly in the manufacturing and electrical and electronics sectors. Until then, most investors are expected to adopt a wait-and-see approach, prioritising capital preservation over risk-taking,' he said. Regionally, market focus is shifting towards renewed US-China trade diplomacy as Chinese Vice Premier He Lifeng is set to lead high-level negotiations in Sweden from July 27-30, ahead of the expiry of the 90-day tariff suspension on Aug 12. "The outcome will be instrumental in shaping regional trade sentiment and broader market tone heading into August,' Mohd Sedek said. Globally, investor attention remains fixed on a packed US macroeconomic calendar, particularly with the upcoming the Federal Open Market Committee meeting on July 30, the June Personal Consumption Expenditure inflation print and July non-farm payrolls, which will provide important policy signals. Rakuten Trade Sdn Bhd equity research vice-president Thong Pak Leng said market participants will turn their focus to China's July Purchasing Managers Index as well as Eurozone Consumer Price Index. For the week just ended, optimism spurred by Prime Minister Datuk Seri Anwar Ibrahim's "appreciation package' and renewed confidence in domestic fiscal support lifted utilities and consumer counters, but the momentum proved short-lived as broad-based selling later overshadowed mid-week support from telco stocks. For the week under review, the benchmark index rose 7.90 points to 1,533.76 on Friday from 1,525.86 a week earlier. The FBM Emas Index increased 26.99 points to 11,506.82 and the FBMT 100 Index gained 28.03 points to 11,269.72, but the FBM Emas Shariah Index slid 8.89 points to 11,528.98, the FBM 70 Index dipped 90.15 points to 16,607.57 and the FBM ACE Index dropped 32.77 points to 4,639.02. By sector, the Financial Services Index jumped 99.4 points to 17,454.23, the Plantation Index reduced 7.10 points to 7,434.79 and the Energy Index went up 0.21 of a point to 739.85. Weekly turnover narrowed to 11.92 billion units worth RM11.43 billion from 15.53 billion units worth RM11.77 billion in the previous week. Main Market volume slid to 6.63 billion units valued at RM9.70 billion compared with 6.73 billion units valued at RM10.07 billion previously. Warrant turnover grew to 7.10 billion units worth RM1.15 billion from 6.83 billion units worth RM966.72 million in the preceding week. ACE Market volume shrank to 1.68 billion units valued at RM577.05 million versus 1.97 billion units valued at RM729.96 million previously. - Bernama
